| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Pier Paolo Pandolfi | Q7191735 |
| Arkaitz Carracedo | Q57415954 | ||
| Andrea Alimonti | Q59542829 | ||
| P2860 | cites work | Mutation and cancer: statistical study of retinoblastoma | Q24618185 |
| A coding-independent function of gene and pseudogene mRNAs regulates tumour biology | Q24632651 | ||
| Targeting the PI3K signaling pathway in cancer | Q24647554 | ||
| Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis | Q24681977 | ||
| Pten dose dictates cancer progression in the prostate | Q24791909 | ||
| PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer | Q27860985 | ||
| Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers | Q28306997 | ||
| Nuclear PTEN levels and G2 progression in melanoma cells | Q28391204 | ||
| Pten is essential for embryonic development and tumour suppression | Q28509238 | ||
| Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems | Q28586004 | ||
| Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells | Q29616552 | ||
| Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. | Q34477787 | ||
| Reduction of Pten dose leads to neoplastic development in multiple organs of Pten (shRNA) mice | Q34479331 | ||
| PTEN hamartoma tumor syndrome: an overview | Q34996547 | ||
| Subtle variations in Pten dose determine cancer susceptibility | Q35055350 | ||
| Suppression of PTEN expression by NF-kappa B prevents apoptosis | Q35544303 | ||
| Tenets of PTEN tumor suppression | Q37154214 | ||
| Analysis of PTEN complex assembly and identification of heterogeneous nuclear ribonucleoprotein C as a component of the PTEN-associated complex | Q37431681 | ||
| Faithfull modeling of PTEN loss driven diseases in the mouse | Q37765216 | ||
| Haplo-insufficiency: a driving force in cancer | Q37815124 | ||
| PTEN downregulates p75NTR expression by decreasing DNA-binding activity of Sp1. | Q39900792 | ||
| Localization of agonist-sensitive PtdIns(3,4,5)P3 reveals a nuclear pool that is insensitive to PTEN expression. | Q40198370 | ||
| Zinc-induced PTEN protein degradation through the proteasome pathway in human airway epithelial cells. | Q40648400 | ||
| Suppression of PTEN expression is essential for antiapoptosis and cellular transformation by oncogenic Ras. | Q42822914 | ||
| Phosphatase activity of nuclear PTEN is required for CDX2-mediated intestinal differentiation of gastric carcinoma. | Q54508403 | ||
| PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention | Q59067116 | ||
| Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues | Q74093343 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 629-633 | |
| P577 | publication date | 2011-01-25 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | PTEN level in tumor suppression: how much is too little? | |
| P478 | volume | 71 |
| Q60924135 | A Soft Coral-Derived Compound, 11-Dehydrosinulariolide, Induces G2/M Cell Cycle Arrest and Apoptosis in Small Cell Lung Cancer |
| Q34181587 | A bistable model of cell polarity |
| Q24320313 | A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes |
| Q36967494 | A novel PTEN gene promoter mutation and untypical Cowden syndrome |
| Q30417988 | A novel PTEN/mutant p53/c-Myc/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapy |
| Q36733736 | Achieving specificity in Akt signaling in cancer |
| Q103826227 | Activation of PAR2 by tissue factor induces the release of the PTEN from MAGI proteins and regulates PTEN and Akt activities |
| Q38757962 | Adenovirus-mediated co-expression of ING4 and PTEN cooperatively enhances their antitumor activity in human hepatocellular carcinoma cells |
| Q37248700 | Adipocyte lineages: tracing back the origins of fat. |
| Q90570508 | Alternative polyadenylation confers Pten mRNAs stability and resistance to microRNAs |
| Q39239168 | Anticancer role of MUC1 aptamer-miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation |
| Q48022708 | Apelin-induced cardioprotection against ischaemia/reperfusion injury: roles of epidermal growth factor and Src. |
| Q97534301 | Autophagy as a modulator of cell death machinery |
| Q28394865 | Chronic inorganic arsenic exposure in vitro induces a cancer cell phenotype in human peripheral lung epithelial cells |
| Q28117749 | Deubiquitylase OTUD3 regulates PTEN stability and suppresses tumorigenesis |
| Q33675285 | Direct effects of metformin in the endometrium: a hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma. |
| Q41630070 | Distinct regulation of alternative polyadenylation and gene expression by nuclear poly(A) polymerases. |
| Q44801430 | Downregulation of PTEN expression in psoriatic lesions |
| Q36204972 | Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model. |
| Q40054562 | ERG overexpression and PTEN status predict capsular penetration in prostate carcinoma |
| Q35882019 | Engineering FKBP-Based Destabilizing Domains to Build Sophisticated Protein Regulation Systems |
| Q38275377 | Engineering PTEN function: membrane association and activity |
| Q33854076 | Engineering ePTEN, an enhanced PTEN with increased tumor suppressor activities |
| Q36464689 | Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL. |
| Q51186316 | Evidence for a genetic basis of urogenital carcinoma in the wild California sea lion. |
| Q33358591 | Genetic polymorphisms altering microRNA activity in psoriasis--a key to solve the puzzle of missing heritability? |
| Q28384465 | HCV infection-associated hepatocellular carcinoma in humanized mice |
| Q37249335 | High-expression of DJ-1 and loss of PTEN associated with tumor metastasis and correlated with poor prognosis of gastric carcinoma |
| Q50199746 | Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer |
| Q37005755 | INPP4B is an oncogenic regulator in human colon cancer. |
| Q36545503 | INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas. |
| Q38251133 | Identifying the role of microRNAs in spinal cord injury |
| Q35986673 | Inactivation of tumor suppressor gene pten in early and advanced gallbladder cancer |
| Q38745227 | KH-type splicing regulatory protein (KHSRP) contributes to tumorigenesis by promoting miR-26a maturation in small cell lung cancer |
| Q36255926 | Keratoacanthoma of the Lip: Activation of the mTOR Pathway, Tumor Suppressor Proteins, and Tumor Senescence |
| Q92759860 | LINC00184 silencing inhibits glycolysis and restores mitochondrial oxidative phosphorylation in esophageal cancer through demethylation of PTEN |
| Q36649018 | Largazole: from discovery to broad-spectrum therapy |
| Q38267349 | Light-regulated microRNAs |
| Q42413905 | Loss and reduced expression of PTEN correlate with advanced-stage gastric carcinoma |
| Q37060963 | Loss of PI(4,5)P2 5-Phosphatase A Contributes to Resistance of Human Melanoma Cells to RAF/MEK Inhibitors. |
| Q35234584 | Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer |
| Q35764742 | Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer |
| Q35057232 | Mechanism of human PTEN localization revealed by heterologous expression in Dictyostelium |
| Q64051999 | Methylation and PTEN activation in dental pulp mesenchymal stem cells promotes osteogenesis and reduces oncogenesis |
| Q28547840 | MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells |
| Q59465999 | Microfluidics: Rapid Diagnosis for Breast Cancer |
| Q41021890 | Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets |
| Q38264216 | Molecular pathways: intercellular PTEN and the potential of PTEN restoration therapy |
| Q92906114 | Multifaceted Regulation of PTEN Subcellular Distributions and Biological Functions |
| Q37968309 | Multiple roles for the p85α isoform in the regulation and function of PI3K signalling and receptor trafficking |
| Q36317685 | Myocardial ischemic post-conditioning attenuates ischemia reperfusion injury via PTEN/Akt signal pathway |
| Q39104408 | NFκB-mediated cyclin D1 expression by microRNA-21 influences renal cancer cell proliferation |
| Q90158781 | Novel miRNA markers for the diagnosis and prognosis of endometrial cancer |
| Q54250883 | Nuclear factor-κB pathway activation and phosphatase and tensin homolog downregulation in psoriasis. |
| Q42117421 | Opening the conformation is a master switch for the dual localization and phosphatase activity of PTEN. |
| Q48391809 | Orphan nuclear receptor TLX functions as a potent suppressor of oncogene-induced senescence in prostate cancer via its transcriptional co-regulation of the CDKN1A (p21(WAF1) (/) (CIP1) ) and SIRT1 genes. |
| Q34360248 | Overview of the biochemical and genetic processes in malignant mesothelioma. |
| Q36652026 | PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma |
| Q38217651 | PI3K/AKT signaling pathway and cancer: an updated review |
| Q28247338 | PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data |
| Q37702754 | PREX1 integrates G protein-coupled receptor and phosphoinositide 3-kinase signaling to promote glioblastoma invasion |
| Q38883994 | PRL-3 Promotes the Malignant Progression of Melanoma via Triggering Dephosphorylation and Cytoplasmic Localization of NHERF1. |
| Q50704883 | PTEN Down-Regulation Promotes β-Oxidation to Fuel Hypertrophic Liver Growth After Hepatectomy in Mice. |
| Q36452913 | PTEN at a glance |
| Q57790325 | PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications |
| Q37049376 | PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma |
| Q42371556 | PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort |
| Q26995683 | PTEN plasticity: how the taming of a lethal gene can go too far |
| Q39176925 | PTEN proteoforms in biology and disease |
| Q24337070 | PTEN suppresses the oncogenic function of AIB1 through decreasing its protein stability via mechanism involving Fbw7 alpha |
| Q38275375 | PTEN-PDZ domain interactions: binding of PTEN to PDZ domains of PTPN13. |
| Q35087328 | PTEN: Multiple Functions in Human Malignant Tumors |
| Q35235757 | Phosphatase and tensin homolog on chromosome 10 is phosphorylated in primary effusion lymphoma and Kaposi's sarcoma |
| Q37406760 | Progesterone receptor isoforms A and B: new insights into the mechanism of progesterone resistance for the treatment of endometrial carcinoma |
| Q24604987 | Protein kinases and phosphatases in the control of cell fate |
| Q35165208 | Protein tyrosine phosphatases PTP-1B, SHP-2, and PTEN facilitate Rb/E2F-associated apoptotic signaling |
| Q39436597 | Repression of cancer cell senescence by PKCι. |
| Q42326441 | Rescue of glandular dysmorphogenesis in PTEN-deficient colorectal cancer epithelium by PPARγ-targeted therapy. |
| Q36899622 | Role of TRPM2 in cell proliferation and susceptibility to oxidative stress |
| Q39285469 | Role of aberrant PI3K pathway activation in gallbladder tumorigenesis |
| Q42355766 | Roles of Polo-like kinase 3 in suppressing tumor angiogenesis. |
| Q92684185 | SHCBP1 regulates apoptosis in lung cancer cells through phosphatase and tensin homolog |
| Q39339428 | SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesis |
| Q36976208 | Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer |
| Q54257572 | Suppression of SHIP2 contributes to tumorigenesis and proliferation of gastric cancer cells via activation of Akt. |
| Q37223362 | Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase/phosphatase |
| Q33678064 | TGF-β induces phosphorylation of phosphatase and tensin homolog: implications for fibrosis of the trabecular meshwork tissue in glaucoma |
| Q64254413 | Targeting PI3K in cancer: mechanisms and advances in clinical trials |
| Q38190918 | Targeting the PI3K/Akt/mTOR pathway in malignancy: rationale and clinical outlook |
| Q28079596 | Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes? |
| Q34330961 | The effect of systemic PTEN antagonist peptides on axon growth and functional recovery after spinal cord injury. |
| Q38148036 | The function, mechanisms, and role of the genes PTEN and TP53 and the effects of asbestos in the development of malignant mesothelioma: a review focused on the genes' molecular mechanisms |
| Q37521382 | The gene dosage of class Ia PI3K dictates the development of PTEN hamartoma tumor syndrome |
| Q37082176 | The microRNA miR-181 is a critical cellular metabolic rheostat essential for NKT cell ontogenesis and lymphocyte development and homeostasis |
| Q36476282 | The prognostic effect of PTEN expression status in colorectal cancer development and evaluation of factors affecting it: miR-21 and promoter methylation |
| Q40150714 | There is a world beyond protein mutations: the role of non-coding RNAs in melanomagenesis |
| Q38871798 | Thymosin alpha 1 suppresses proliferation and induces apoptosis in breast cancer cells through PTEN-mediated inhibition of PI3K/Akt/mTOR signaling pathway |
| Q90394311 | Tumor Suppressors in Chronic Lymphocytic Leukemia: From Lost Partners to Active Targets |
| Q58609591 | Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network |
| Q42906390 | Upregulation of micro-ribonucleic acid-128 cooperating with downregulation of PTEN confers metastatic potential and unfavorable prognosis in patients with primary osteosarcoma |
| Q35889659 | Variants on the promoter region of PTEN affect breast cancer progression and patient survival |
| Q26825780 | What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway |
| Q42642212 | Where Birt-Hogg-Dubé meets Cowden syndrome: mirrored genetic defects in two cases of syndromic oncocytic tumours |
| Q27000495 | Wrecked regulation of intrinsically disordered proteins in diseases: pathogenicity of deregulated regulators |
| Q64274877 | mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy |
| Q38954890 | miR-17-92 cluster promotes cholangiocarcinoma growth: evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator |
| Q43416243 | miR-508 sustains phosphoinositide signalling and promotes aggressive phenotype of oesophageal squamous cell carcinoma. |
Search more.